I believed you until you said turning profitable later this year. really? did anyone else hear that? That would definitely have pushed the stock much much higher.
I agree. also, the debt's not due for a couple of years so we have some time. Let's hope we can get the revenues up and get to a level of profitability.
Purely technicals from here. Will fill the gap down to $20ish. Look at the chart...that's where the max 50 DMA is. If it goes down to the max 200 DMA, even lower. Looks much like the DNDN chart from $50's down. Unfortunately, I rode that one all the way down. This time around, I'm short from the mid-50's and will ride it all the way down. Not going against the trend this time around...learned my lesson.
It was really interesting how everyone came out of the woodwork to bash dndn today. I was thinking to myself...hmmm...there must be some really good news on the horizon. Won't buy more as I already own 15K+ shares but hoping it goes up and I can cash out on some of it.
if you trust technicals, this will have to fall at least $20-$25 or so to fill the gap. i've never seen a chart that goes one way without revisiting support levels at some point. dndn was the same in the $50s...you knew it would crash hard from there. by this time next year, MDVN's chart will look similar to dndn but might reach support and bounce back whereas dndn just kept going down.
agreed...who the hell would want a buyout now? We have to wait for those catalysts and then get a buyout after our shares have recovered. We are soooo undervalued right now for a growing (albeit not as fast as we all anticipated) biotech company.
that would be terrible. I pray there's no buyout until we build some value in the stock price and uncover some great results with Nuvenge, etc. It would suck to be bought out at $11.
I own a ton of DNDN and the only problem w/ DNDN is the growth after 2 years. I'm hoping DNDN can increase sales, get into Europe and have a huge year but so far, I've been disappointed.
Great article about the potential worth of their diabetes drug.
that looks to be where the lines from the downward channel and upward channel merge...technically speaking, that's where I see it happening. I really wanted $19 though.
sure...that makes a lot of sense...let's not sell Benlysta so we reduce our revenues to hurt hgsi. come on.
like watching paint dry. I finally got my paperwork from TDAmeritrade and I discarded all of it as there's no way I'm going to give them my shares for $13. Next year, it'll be worth way more if this acquisition doesn't happen. I'm in it for the long haul...not a day trader.
Here's the link and it says looks like GSK will extend the offer beyond 6/7.
I got out at 26 for a quick profit...it could very well have gone the other way but seemed way oversold given how much it's declined over the past 18 months...even with the terrible guidance.